Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab and Chemotherapy Induction in Unresectable Stage III NSCLC
NCT05940532Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Jun 2023; status: recruiting.
02
Drugs
sugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05940532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940532.